The Arf-like protein Arl13b has been implicated in ciliogenesis and Sonic hedgehog signaling. Furthermore, we have previously shown that it regulates endocytic recycling traffic and interacts with actin. Herein, we report that the non-muscle myosin heavy chain IIA, also known as Myh9, is an Arl13b effector. Moreover, we found that both proteins localized to circular dorsal ruffles (CDRs) induced by platelet-derived growth factor stimulation and are required for their formation. CDRs are ring-shaped actin-dependent structures formed on the dorsal cell surface and are involved in diverse processes, such as macropinocytosis, integrin recycling, internalization of receptor tyrosine kinases and cell migration. We found that Arl13b or Myh9 silencing impaired cell migration, suggesting that Arl13b is required for this function through the interaction with Myh9. Moreover, Arl13b silencing impaired neural crest cell migration in zebrafish embryos. Furthermore, we showed that Arl13b is required for the formation of CDRs in migrating cells. Thus, our results indicate a new role for Arl13b in actin cytoskeleton remodeling through the interaction with Myh9, by driving the formation of CDRs necessary for cell migration.
INTRODUCTION
Cell migration is essential during development and wound healing, and has been implicated in human diseases, such as atherosclerosis and cancer (Ridley et al., 2003, Raftopoulou and Hall, 2004) . At the intracellular level, cell migration has been shown to be regulated by polarized vesicle trafficking and recycling of internalized proteins to the leading edge of migrating cells (Fletcher and Rappoport, 2010; Ulrich and Heisenberg, 2009) . During this process, extracellular growth factors activate receptor tyrosine kinase (RTK)-dependent signaling, leading to extensive actin cytoskeleton remodeling and to the formation of unique specialized structures, such as circular dorsal ruffles (CDRs), lamellipodia and filopodia. CDRs are highly dynamic ring-shaped structures that are rich in filamentous actin (F-actin) , and form on the dorsal surface of epithelial cells and fibroblasts in response to stimulation with growth factors, such as platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) (Hoon et al., 2012) . Moreover, CDRs have been implicated in macropinocytosis (Dowrick et al., 1993) , recycling of integrins (Gu et al., 2011) , rapid actin cytoskeleton remodeling during cell migration (Buccione et al., 2004) , and in the internalization and sequestration of a number of RTKs, leading to their downregulation (Orth and McNiven, 2006) .
Members of the Ras superfamily of small G proteins have been shown to play key roles in CDR formation. For instance, Rac1 and Rab5 have been found to be necessary for CDR formation by controlling intracellular trafficking through early endosomes (Lanzetti et al., 2004; Palamidessi et al., 2008) . Small G proteins can cycle between inactive GDP-bound and active GTPbound conformations. When in their GTP-bound form, they recruit effector proteins that mediate vesicle budding from donor organelles, vesicle transport along microtubules or actin filaments, and tethering and fusion of vesicles to acceptor compartments. Therefore, they control protein secretion, endocytosis, recycling and degradation, among other functions, and are widely recognized as essential regulators of intracellular trafficking.
ADP-ribosylation-factor-like (Arl) proteins belong to the Arf family of small G proteins and are thought to regulate vesicle tethering to acceptor membrane compartments, as well as cytoskeleton organization (Donaldson and Jackson, 2011) . However, their functions are still largely unknown and, for most of them, there are no known effectors. Interestingly, several Arl proteins, namely Arl3, Arl6 and Arl13b, have been associated with the primary cilium, a mechanosensory organelle involved in signal transduction. Arl13b was identified as one causal locus for the ciliopathy Joubert syndrome, an autosomal recessive disorder characterized by congenital cerebellar ataxia, hypotonia, oculomotor apraxia, mental retardation, cystic kidneys and polydactyly (Cantagrel et al., 2008) . Arl13b hnn mutant mice [also known as hennin mice (hnn)] mimic the phenotype of Joubert syndrome patients, and show coupled defects in cilia structure and Sonic hedgehog (Shh) signaling (Caspary et al., 2007; Larkins et al., 2011, Horner and .
Recently, we demonstrated that Arl13b regulates endocytic recycling traffic (Barral et al., 2012) . Additionally, we have observed that Arl13b colocalizes with the actin cytoskeleton and that it interacts with actin. Herein, we describe a new role for Arl13b in the formation of CDRs. Moreover, we found that Arl13b is required for cell migration, both in vitro and in vivo and that it is necessary for CDR formation in migrating cells. Furthermore, we identified the motor protein non-muscle myosin heavy chain IIA, also known as Myh9, as an Arl13b effector. Myh9 is one of the three isoforms of the non-muscle myosin II heavy chain found in humans and has been implicated in the generation of cell polarity, cell motility, directional cell migration and cell-cell adhesion (Conti and Adelstein, 2008; Vicente-Manzanares et al., 2009 ). In addition, there is evidence that Myh9 is involved in the docking and fusion events of the secretory pathway that take place in the apical domain, below the plasma membrane (Bond et al., 2011) . Interestingly, we found that Myh9 is also necessary for the formation of CDRs induced by PDGF stimulation and for the interaction between Arl13b and actin. Thus, our findings suggest that the mechanism by which Arl13b and Myh9 regulate actin remodeling is by driving the formation of CDRs that are required for cell migration.
RESULTS

Arl13b localizes to circular dorsal ruffles
We have previously found that Arl13b interacts with actin and colocalizes with actin filaments and cortical actin (Barral et al., 2012) . We extended these results and found that Arl13b localizes in actin-rich peripheral regions that are consistent with lamellipodia and filopodia (Fig. 1A) . We also analyzed whether Arl13b was present in other actindependent structures. Strikingly, when NIH-3T3 cells expressing wild-type Arl13b tagged with EGFP (Arl13b-wt-EGFP) were treated with the growth factor PDGF-BB (the PDGF homodimer comprising two PDGFB chains) for 20 minutes to induce CDR formation, we found that Arl13b localized to Fig. 1 . Colocalization of Arl13b with actin-rich structures. (A) NIH-3T3 cells expressing Arl13b-wt-EGFP (Arl13b wt-EGFP) were fixed and stained with Alexa-Fluor-568-conjugated phalloidin. At the cell periphery, Arl13b localizes in actinrich structures that are consistent with lamellipodia (arrows) and filopodia (arrowhead). (B) NIH-3T3 cells expressing Arl13b-wt-EGFP were stimulated with PDGF-BB (30 ng/ml) for the indicated times, fixed and stained with Alexa-Fluor-568-conjugated phalloidin to label actin or with mouse monoclonal anti-cortactin antibody. Enlarged views of the indicated sections are shown in the insets. Scale bars: 10 mm. these structures, identified by the presence of both F-actin and the specific CDR marker cortactin (Ammer and Weed, 2008) (Fig. 1B) . Moreover, when human primary fibroblasts were transduced with lentiviruses encoding Arl13b-wt-EGFP, upon PDGF stimulation, the protein was readily identified in CDRs labeled by phalloidin or cortactin, suggesting that this localization is not exclusive to transformed cell lines (supplementary material Fig. S1A ). Furthermore, to study Arl13b localization during CDR formation, F-actin and Arl13b were monitored by time-lapse microscopy in PDGF-stimulated NIH-3T3 cells coexpressing Arl13b-wt-EGFP and Lifeact-ruby, which binds F-actin. We observed the formation of a circular structure, identified as a CDR because it is enriched in F-actin, within the first 20 minutes of PDGF stimulation (supplementary material Fig. S1B ; Movie 1). This suggests that the localization of Arl13b in CDRs is not an artifact of fixation and occurs in live cells. Taken together, these results show that Arl13b becomes rapidly concentrated in CDRs in response to growth factor stimulation.
Arl13b is required for circular dorsal ruffle formation
Given that Arl13b interacts with actin and localizes to CDRs, we asked whether it can regulate their formation. For this, we used two distinct short hairpin RNAs (shRNAs) targeting Arl13b, to achieve between 50 and 88% reduction in Arl13b protein levels, as determined by immunoblotting (supplementary material Fig. S2A ). CDRs were present in ,49% of cells transduced with shRNA control and stimulated with PDGF-BB for 10 minutes, and in 47% of control mock-transfected cells, whereas only ,19.5% of the Arl13b-silenced cells formed CDRs, which were also noticeably smaller ( Fig. 2A,B) . Furthermore, we quantified CDR formation in Arl13b-deficient mouse embryonic fibroblasts (MEFs) over a timecourse and observed that the formation of CDRs was impaired in Arl13b hnn MEFs throughout the 30 minutes of PDGF stimulation, as compared to wild-type MEFs (supplementary material Fig. S2B,C) . Finally, we confirmed that in human primary fibroblasts, Arl13b silencing also impaired CDR formation (supplementary material Fig. S2D ). Importantly, this defect in CDR formation was rescued by exogenous expression of Arl13b-wt-EGFP (Fig. 2B) , showing that the impairment in CDR formation upon Arl13b silencing is not an off-target effect. Arl13b differs substantially from other Arls because it contains a long C-terminal domain of largely unknown function. We have previously found that Arl13b 1-193 truncation mutant, which does not contain the C-terminal region of Arl13b, is unable to colocalize with the actin cytoskeleton (Barral et al., 2012) . As a further control for the specificity of the impairment of CDR formation in Arl13b-depleted cells, we expressed exogenous EGFP-tagged Arl13b in cells where the expression of Arl13b was silenced. We observed that unlike Arl13b-wt-EGFP, Arl13b-1-193-EGFP was not capable of rescuing CDR formation after Arl13b silencing, further confirming the specificity of the rescue (Fig. 2B) . Furthermore, a mock control of the transfection confirmed the specificity of the rescue obtained by exogenous expression of Arl13b-wt-EGFP. By contrast, cells overexpressing Arl13b-wt-EGFP displayed an ,2.5-fold increase in CDR formation upon PDGF stimulation for 20 minutes, when compared to cells expressing EGFP or Arl13b-1-193-EGFP (Fig. 2C) . Taken together, these results strongly suggest that Arl13b is required for the formation of PDGF-induced CDRs.
Arl13b associates with macropinosomes and with early and recycling endosomes
CDRs have been implicated in macropinocytosis, a regulated form of endocytosis that mediates the non-selective uptake of fluid-phase cargo (Swanson, 2008; Kerr and Teasdale, 2009 ). This process can be monitored by following fluid-phase markers, such as dextran (Kerr and Teasdale, 2009) . Given that Arl13b is necessary for CDR formation, we investigated whether Arl13b-labeled CDRs matured into macropinosomes. To this end, NIH-3T3 cells expressing Arl13b-wt-EGFP were incubated with dextran in the presence of PDGF, and dextran uptake was monitored by confocal microscopy over a timecourse. After 5 minutes of PDGF stimulation, we observed Arl13b in circular structures that were labeled by F-actin but did not contain dextran (Fig. 3A) . Therefore, they can be identified as CDRs, which are open to the extracellular milieu and are not able to retain fluid-phase markers. Interestingly, after 10 minutes of PDGF stimulation, cells expressing Arl13b-wt-EGFP showed dextran accumulation in structures that contained Arl13b but were negative for F-actin (Fig. 3A) . These can be identified as macropinosomes, which are intracellular structures that retain fluid-phase markers and are devoid of F-actin. Thus, these observations suggest that after being recruited to CDRs, Arl13b is incorporated into macropinosomes.
Next, we sought to assess the localization of Arl13b after a longer incubation with PDGF, because after macropinosome disassembly, cargo that has been taken up through CDRs, such as integrins, traffics through early and recycling endosomes (Gu et al., 2011) . Interestingly, we observed that after 30 minutes of PDGF stimulation, Arl13b partially colocalized with early endosome markers (EEA1 and Rab5a), as well as with a recycling endosome marker (transferrin), in small vesicles dispersed throughout the cytoplasm (Fig. 3B-D ). This supports our previous studies, where we found a role for Arl13b in the recycling pathway (Barral et al., 2012) . Taken together, this data suggests that Arl13b is internalized upon growth factor stimulation in CDRs and traffics through early and recycling endosomes.
Arl13b is required for in vitro and in vivo cell migration
In order to investigate whether Arl13b is associated with CDRdependent functions, we examined whether Arl13b is required for cell migration. For this, we monitored cell migration in two different ways, namely by using scratch 'wound healing' and transwell migration assays. In the former, a monolayer of cells was scratched with a pipette tip. The migration of cells to close the 'wound' was assessed after 16 hours by measuring the area free of cells. Strikingly, Arl13b silencing resulted in a significant delay (,50%) in PDGF-dependent wound closure in NIH-3T3 cells (Fig. 4A,B) . Next, we confirmed that Arl13b deficiency in Arl13b
hnn MEFs also resulted in delayed wound closure (supplementary material Fig. S3A,B) . Similarly, we observed that Arl13b silencing in HeLa cells led to impairment in wound closure (supplementary material Fig. S3C ), suggesting that Arl13b requirement for cell migration is general and conserved. Moreover, given that HeLa cells do not possess cilia (Alieva et al., 1999) , this function is presumably independent of the primary cilium, where Arl13b has a known role. Conversely, when Arl13b-wt-EGFP was overexpressed in NIH-3T3 or HeLa cells, an increase in the percentage of wound closure was observed when compared with cells overexpressing Arl13b-1-193-EGFP, EGFP or non-transfected cells ( Fig. 4C ; supplementary material Fig. S3D ). Furthermore, cell migration was assessed using a modified Boyden chamber transwell assay. Consistent with the scratch wound healing assays, this approach revealed that Arl13b-silenced cells were defective in PDGF-induced cell migration (Fig. 4D,E) . Hence, these results show that Arl13b is required for cell migration, as measured by wound healing and transwell assays.
Interestingly, we observed that Arl13b was recruited to the leading edge of cells at the forefront of closing wounds, where it colocalizes with the actin cytoskeleton (supplementary material Fig. S4A ). Moreover, CDRs have been implicated in the transition from static to motile cell states (Gu et al., 2011; Sero et al., 2011) . Therefore, in order to investigate whether Arl13b-deficient cells cannot migrate properly owing to deficient CDR formation, immunofluorescence analysis was carried out on migrating cells in the wound healing model. For this, NIH-3T3 cell monolayers were fixed 4 hours after scratching, in the presence of PDGF. Typical CDRs, identified by the presence of both phalloidin and cortactin, were observed in ,50% of shRNA control cells lining the edge of the closing wounds, showing that migrating cells possess CDRs. However, in Arl13b-silenced cells, only ,15% of the cells lining the wound edges formed CDRs (Fig. 4F,G) . Importantly, Arl13b silencing efficiency was confirmed by immunoblotting (supplementary material Fig. S4B ). Taken together, these results suggest that the observed defects in cell migration in cells depleted of Arl13b can be associated with the significant decrease in CDR formation in cells that are migrating into closing wounds.
Finally, we assessed the Arl13b requirement for cell migration in a well-established in vivo model. For this, we used the sox10 gene, which is expressed during neural crest cell migration from the neural tube into the somite region in zebrafish embryos (Dutton et al., 2001) . At 24 hours post-fertilization (hpf), migratory neural crest cells, labeled by sox10, gradually migrated from the neural tube into the trunk of wild-type embryos (Fig. 4H) . However, when zebrafish embryos were treated with a morpholino antisense oligonucleotide to temporarily silence Arl13b expression, there was a significant delay in the onset of migration of neural crest cells expressing sox10 when compared to stage-matched siblings (Fig. 4H) . Importantly, this defect in neural crest cell migration could be rescued when Arl13b morpholino was injected into Arl13b transgenic zebrafish embryos that overexpress mouse Arl13b, which is not targeted by the morpholino (Borovina et al., 2010) (Fig. 4H) . Taken together, these results show that Arl13b is required for cell migration both in vitro and in vivo, probably through the formation of CDRs at sites of migration. To determine the molecular mechanism by which Arl13b interacts with actin and mediates CDR formation, we attempted to identify Arl13b-binding partners. Moreover, by coimmunoprecipitation of cell extracts loaded with a nonhydrolyzable analog of GTP, GTPcS, we specifically attempted to identify Arl13b effectors that bind to the active form of the protein. Interestingly, we were able to detect a band of ,230 kDa in one-dimensional SDS-PAGE that was absent in the control (IgG) and GDP-loaded lanes (Fig. 5A ). After mass spectrometry of tryptic peptides, this band was identified as the non-muscle heavy chain myosin IIA, which is also known as Myh9. This myosin is a ubiquitously expressed contractile protein that has been implicated in the regulation of cell spreading and directional cell migration in response to several stimuli (Vicente-Manzanares et al., 2009; Conti and Adelstein, 2008) . We confirmed the interaction between Myh9 and Arl13b by co-immunoprecipitation using an anti-Arl13b antibody followed by detection of Myh9 in NIH-3T3 cell extracts by immunoblotting (Fig. 5B ). In agreement with the proteomics approach, a band with the expected size of about 230 kDa was observed when the co-immunoprecipitation was performed in the presence of GTPcS, but not in the presence of GDP or in control reactions where an isotype control antibody was used (Fig. 5B ). This result shows that Myh9 interacts with Arl13b only when Arl13b is in its active state, that is, Myh9 is a bona fide Arl13b effector. Importantly, when a similar strategy was employed in Arl13b-depleted cells, namely Arl13b hnn MEFs, the interaction between Arl13b and Myh9 could not be detected (Fig. 5C) , showing the specificity of the binding.
We have previously shown that Arl13b co-immunoprecipitates with b-actin (Barral et al., 2012) . Interestingly, we now observed that Arl13b interacts preferentially with b-actin when is in its active or GTP-bound form, with a slight but significant increase in binding in response to PDGF (supplementary material Fig.  S4C ). Finally, to test whether Myh9 is required for the interaction between Arl13b and actin, we studied the effect of Myh9 silencing on this interaction. Strikingly, we observed that in NIH-3T3 cells silenced for Myh9 (Fig. 5E ), the interaction of Arl13b with b-actin was abolished (Fig. 5D) . Thus, these data strongly suggest that Myh9 binds to Arl13b in its GTP-bound form and is necessary for the interaction between Arl13b and actin.
Myh9 is required for circular dorsal formation and cell migration
To know if Myh9 colocalizes with Arl13b, we used a polyclonal anti-Myh9 antibody to detect the protein in NIH-3T3 cells. In non-stimulated cells, Myh9 colocalized with actin stress fibers in the cytosol and in lamellipodia at the cell periphery (Fig. 6A ). After treatment with PDGF, we observed that Myh9 localized to CDRs, which were decorated by phalloidin and cortactin. Moreover, when NIH-3T3 cells transiently expressing Arl13b-wt-EGFP were stimulated with PDGF and immunostained with anti-Myh9 antibody, we observed a striking colocalization between Arl13b and Myh9 in CDRs (Fig. 6A) . Furthermore, in Myh9-silenced cells, CDR formation was impaired upon PDGF stimulation for 20 minutes, suggesting that, similar to Arl13b, Myh9 is required for the formation of CDRs (Fig. 6B and  supplementary material Fig. S4D ). The specificity of this effect was shown by efficient rescue of the CDR formation impairment through the exogenous expression of Myh9-EGFP, using EGFP as a negative control (Fig. 6B) . To determine whether Arl13b-mediated CDR formation requires Myh9, Arl13b-wt-EGFP was transiently expressed in control or Myh9-silenced cells. We found that the striking localization of Arl13b in CDRs observed in control cells was reduced when Myh9 was silenced (Fig. 7A,B) , suggesting that the recruitment of Arl13b to CDRs is dependent on Myh9. Moreover, expression of Arl13b-wt-EGFP significantly enhanced PDGF-induced CDR formation in control cells but not in Myh9-silenced cells (Fig. 7C) . Taken together, these results suggest that Myh9 is necessary for Arl13b-mediated CDR formation and support our previous observations that Arl13b is specifically localized in CDRs upon PDGF-stimulation. Interestingly, Myh9 has previously been shown to be required for cell migration (Betapudi et al., 2006; Even-Ram et al., 2007) . Given that we found that Myh9 is an Arl13b effector, and that Arl13b is required for cell migration, we examined the role of Myh9 in cell migration in response to PDGF stimulation. Transfection of NIH-3T3 cells with small interfering RNA (siRNA) targeting Myh9 reduced the percentage of wound closure by half, when compared with siRNA control, confirming previous studies (Fig. 7D,E) . Thus, our data strongly suggests that Arl13b regulates CDR formation through the interaction with Myh9.
DISCUSSION
Arl13b has been described to be involved in ciliogenesis and Shh signaling (Caspary et al., 2007; Larkins et al., 2011) . Recently, we also found that Arl13b regulates endocytic recycling traffic and that it associates with the actin cytoskeleton and interacts with actin (Barral et al., 2012) . Here, we identify a new role for Arl13b in the formation of CDRs and in cell migration. In particular, we found that Arl13b becomes associated with the actin cytoskeleton that encircles CDRs in response to growth factor stimulation, and with the macropinosomes that form after CDR closure. CDRs constitute important platforms for sequestration and internalization of membrane-bound proteins, such as growth factor receptors, and also exert an important role in the fast remodeling of the actin cytoskeleton during cell migration. In recent years, several reports have identified new regulators of CDRs (Hoon et al., 2012) . Previous studies have shown that the Rac, Ras and Rab5 small GTPases play a role in the regulation of CDR formation (Palamidessi et al., 2008) . In addition, overexpression of Arf GTPase-activating proteins (GAPs), such as ASAP1 and ASAP3, has been shown to strongly inhibit CDR formation (Randazzo et al., 2000) . In another study, the Arf GAP ARAP1 has been shown to regulate CDR size through Arf1 and Arf5 (Hasegawa et al., 2012) . However, to our knowledge, Arl13b is the first Arl reported to date to localize to CDRs and to regulate their formation. Furthermore, CDRs have been associated with cell migration (Hoon et al., 2012) . Supporting an important function for Arl13b in the formation and function of these structures, we have shown that cells silenced for Arl13b are defective in CDR formation and cell migration. Conversely, overexpression of Arl13b promotes CDR formation and cell motility. Importantly, we have also shown that PDGF-stimulated cell migration is accompanied by an increase in the formation of Arl13b-positive CDRs in migrating cells. These findings suggest that Arl13b is involved in growth-factor-induced actin remodeling and provide insights into the molecular mechanism by which Arl13b is necessary for cell migration. Interestingly, it has recently been shown that Arl13b in primary cilia is required for efficient interneuronal migration into the dorsal cerebral cortex (Higginbotham et al., 2012) . In particular, those authors observed that Arl13b is required for ciliary localization of receptors for interneuronal migration guidance cues, such as 5-hydroxytryptamine (serotonin) receptor subtype 6 (5-HTR6). In this study, we have shown that HeLa cells, which lack primary cilia, display impaired cell migration when Arl13b is silenced. This suggests that the role of Arl13b in cell migration is more general and independent of cilia. Moreover, we monitored the migration of neural crest cells in vivo in a vertebrate model organism, the zebrafish. Whether cilia are present in trunk neural crest is not yet fully clear. Nevertheless, this experiment confirmed that Arl13b deficiency reduces the migration of neural crest cells, a defect that could be rescued by the exogenous expression of the protein in Arl13b transgenic zebrafish. Small G proteins can bind various effectors, such as motors, kinases and phosphatases, in their GTP-bound active conformation. Herein, we have identified a new Arl13b effector, the non-muscle myosin heavy chain IIA, also known as Myh9, which interacts with Arl13b only in its GTP-bound form. To our knowledge, Myh9 is the first bona fide Arl13b effector found to date. Myh9 is one of three distinct isoforms of the non-muscle myosin II heavy chain, an actindependent motor protein involved in the regulation of cell adhesion, cell migration and tissue architecture (Vicente-Manzanares et al., 2009) . Previous studies have shown that Myh9 depletion by siRNA results in defects in cell migration and lamellar spreading (Betapudi et al., 2006) . Moreover, Myh9 has been shown to be required for internalization of EGF (Kim et al., 2012) . We found that Myh9 and Arl13b colocalize in PDGF-induced CDRs and that silencing of Myh9 expression by siRNA impairs CDR formation. Similar to what has been described by others, we confirmed that Myh9 silencing impairs cell migration. We have also found that the interaction between Arl13b and actin requires Myh9. However, it remains to be established whether the Myh9 interaction with Arl13b is direct and, if so, what is (are) the domain(s) involved in the interaction.
Cell migration hinges on trafficking of signaling and adhesion molecules towards the leading edge, a process that requires the regulation of cytoskeletal and vesicle trafficking machineries. Impairment of the endocytic and/or exocytic trafficking of integrins dramatically affects the polarity and directionality of cell migration (Caswell and Norman, 2008) . In addition, it has been shown that CDRs recruit cell surface integrins and internalize them through macropinocytosis for recycling towards the leading edge of migrating cells (Gu et al., 2011) . Given that we have shown that Arl13b regulates endocytic recycling traffic (Barral et al., 2012) and found that, upon PDGF stimulation, Arl13b associates with macropinosomes and with early and recycling endosomes, it is plausible that Arl13b is involved in integrin recycling towards the leading edge in growth-factor-stimulated cell migration. However, this remains to be established. Thus, our results uncover an important function for Arl13b in processes that are dependent on actin cytoskeleton remodeling and culminate with cell migration, and suggest that the interaction between Arl13b and Myh9 is necessary for the generation of contractile forces that are required for this process.
MATERIALS AND METHODS
Cell culture
Cell culture reagents were obtained from Invitrogen. HeLa cells were maintained at 37˚C and 5% CO 2 , in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Invitrogen), 100 U/ml penicillin G, 100 mg/ml streptomycin, 2 mM Lglutamine and 20 mM HEPES (Invitrogen). NIH-3T3 cells were maintained in the same medium with 10% bovine calf serum (Sigma), instead of FBS. Wild-type and Arl13b hnn immortalized mouse embryonic fibroblasts (MEFs, a kind gift of Tamara Caspary, Department of Human Genetics, Emory University, Atlanta, GA) were maintained in dishes coated with 0.2% gelatin (Sigma) in the same medium as HeLa cells, further supplemented with 1 g/l sodium bicarbonate. Primary human fibroblasts were established from skin biopsies and grown in the same medium as HeLa cells with 5% FBS (Invitrogen). To stimulate CDR formation and cell migration, cells were serum-starved for the indicated periods, followed by PDGF-BB (Sigma) addition at a final concentration of 20-30 ng/ml for the indicated periods, before being analyzed.
Transfection and constructs
Transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions and experiments performed 24 hours after transfection. Arl13b-wt-EGFP construct was a kind gift from Kenji Kontani (University of Tokyo, Japan). Arl13b-1-193-EGFP mutant was as described previously (Barral et al., 2012) . Lifeact-ruby plasmid was obtained from Abp140-17aaRuby-nos1-39UTR (B007) (modified by R. Mateus, CEDOC, Riedl et al., 2008) . Rab5a was amplified by PCR using primers 59-CAGCGAATTCATGGCTAATCGAGGAGCAACAAGAC-CCAAC-39 (forward) and 59-ACACGTCGACGGAATAGCCAACA-TGA-39, and then cloned into pcDNA ENTRBPV5 mcherry-C2 using EcoRI/SalI. pcDNA ENTR BP V5 mcherry-C2 was constructed on a backbone of pcDNA6.2/GW/EmGFP (Invitrogen), an expression mammalian vector with Gateway technology (Invitrogen), by swapping EmGFP by V5 and polylinker, using DraI. mCherry was amplified from pCMV myc-mCherry, using 59-GATCAGATCTATGGTGAGCAAG-GGCGAGGAGGATAAC-39 (forward) and 59-TCGAGTCCTTGTACA-GCTCGTCCATGCGCCG-39 (reverse) as primers, and then cloned using BglII/XhoI. siRNA smart pool against Myh9 and siRNA genome nontargeting sequence no. 3, used as control, were transfected with Dharmafect 1 reagent (Dharmacon), according to the manufacturer's instructions. Experiments were performed after 72-96 hours of transfection with siRNAs.
Cell transduction
NIH-3T3, HeLa or primary human fibroblasts were plated at 2610 5 cells per well on six-well plates and infected with shRNA-encoding lentiviruses the next day. For this, 6 mg/ml polybrene (hexadimethrine bromide, Sigma) was added to the cells before the virus. After 24 hours, 2 mg/ml puromycin (Sigma) was added and cells selected for at least a .100 cells counted per condition). (D) Myh9-silenced and control cells grown to confluence were serum-starved and the monolayer was scratched using a pipette tip. Wound closure was monitored for 6 hours. Representative images for both control siRNA and siRNA for Myh9 are shown. (E) The wound area was measured at 0 and 6 hours. Wound closure (%), quantified as described in Materials and Methods was determined in three independent experiments. *P,0.05 (B, Student's t-test); ***P,0.001 (C,E; two-way ANOVA).
week before being assayed. The shRNA sequences for human cells and the negative control sequence (Mission) are described elsewhere (Barral et al., 2012) . For mouse cells, the shRNA sequences are: F2, 59-CGGCCTTGATAATGCTGGTAA-39; F3, 59-GCAAAGGACTTTG-ATGCCTTA-39; and F5, 59-CCTGTCAGAAAGGTGACACTT-39. Primary human fibroblasts grown on coverglasses placed inside 24-well plates (1610 4 cells per well) were infected with L13 Arl13b-EGFP lentivirus (a kind gift from Tamara Caspary) in the presence of 6 mg/ml polybrene for 5 days. Cells were then serum-starved for 5 hours in DMEM supplemented with 0.5% BSA, and CDR formation was stimulated by the addition of PDGF-BB (20 ng/ml, Sigma).
Immunoblotting and immunoprecipitation
Cells were lysed in cold lysis buffer (50 mM Tris-HCl pH 7.4, 0.1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2 mM MgCl 2 and 1 mM DTT), in the presence of protease and phosphatase inhibitors, for 30 minutes on ice, followed by centrifugation at 12,000 g for 15 minutes at 4˚C. Protein concentration was determined using the DC protein assay kit (Bio-Rad) and equal amounts (50 mg) of each sample were loaded on 8-10% SDS-polyacrilamide gels, transferred onto nitrocellulose membranes in transfer buffer (25 mM Tris, 192 mM glycine, 0.025% SDS and 20% methanol) for 90 minutes at 500 mA and processed for immunoblotting. Membranes were blocked with blocking buffer (5% skimmed milk and 0.1% Tween-20 in PBS) and the antibodies incubated in the same buffer. Affinitypurified rabbit polyclonal anti-Arl13b antibody (Barral et al., 2012 ) was used at 3 mg/ml, anti-GAPDH antibody (SicGen) at 0.2 mg/ml, anti-Myh9 antibody (Sigma) at 1 mg/ml. Horseradish peroxidase (HRP)-conjugated secondary antibodies (GE Healthcare) were used at 0.4 mg/ml. Blots were developed with the Immun-Star TM WesternC TM chemiluminescent kit (BioRad) according to the manufacturer's instructions and a Molecular Imager Chemidoc XRS (Bio-Rad) was used to detect the chemiluminescence. Band intensities were quantified using ImageJ software and normalized using GAPDH as a loading control. For immunoprecipitation, cell lysates (1.5 mg total protein) were pre-cleared for 1 hour with Protein-G-Sepharose beads (Sigma). GTPcS (0.5 mM, Sigma) or GDP (5 mM, Sigma) were added to the pre-cleared lysates for 15 minutes at room temperature. Immunoprecipitation was performed using anti-b-actin (Sigma, clone AC-15, 1 mg/ml) or affinity purified rabbit polyclonal anti-Arl13b antibody (3 mg/ml; Barral et al., 2012) for 16 hours at 4˚C with rotation. Protein-G-Sepharose beads were then added and mixed for 4 hours at 4˚C. Beads were recovered by centrifugation, washed once with lysis buffer with a high salt concentration (500 mM NaCl), three times with lysis buffer, and finally were resuspended in Laemmli sample buffer. After boiling at 95˚C for 5 minutes, the immunoprecipitates were resolved by 8-10% SDS-PAGE followed by immunoblotting with anti-Myh9 or anti-Arl13b antibodies or visualization with Colloidal Coomassie BB (Neuhoff et al., 1988) .
Dextran and transferrin internalization assay
To analyze macropinocytosis, NIH-3T3 cells were transfected with Arl13b-wt-EGFP for 24 hours, serum-starved for 5 hours and further stimulated with PDGF-BB (25 ng/ml) together with 0.3 mg/ml tetramethylrhodaminelabeled lysine-fixable 10 kDa dextran (Invitrogen) in serum-free DMEM for 5, 10 or 20 minutes at 37˚C. The cells were washed three times with prechilled PBS, fixed with 4% paraformaldeyde overnight and then stained with Alexa-Fluor-568-conjugated phalloidin (Invitrogen). The analysis was performed using a Zeiss 710 LSM confocal microscope equipped with a Plan-Apochromat 6361.40 NA oil Ph3 lens and Zeiss Zen 2010 software. For transferrin recycling, NIH-3T3 cells were transfected with Arl13b-wt-EGFP for 24 hours and serum-starved for at least 1 hour and then incubated with PDGF-BB (25 ng/ml) and Alexa-Fluor-546-conjugated transferrin (10 mg/ml, Invitrogen) for 30 minutes at 37˚C. The cells were then rinsed in PBS and fixed immediately.
Transwell migration and scratch wound healing assays
Transwell migration assays were performed using modified Boyden chambers. The underside of the polycarbonate membrane (8-mm pore size; Corning) was coated for 16 hours at 4˚C with 10 mg/ml fibronectin (Sigma), washed once with PBS and the chamber filled with DMEM containing 0.5% BSA (starvation medium), with the coated surface facing downward. Cells silenced for Arl13b with shRNAs (F2, F3 and F5) were serum-starved for 5 hours, counted and 1610 5 cells (in 100 ml) added to the upper chamber compartment for each condition. After 2 hours of incubation at 37˚C and 5% CO 2 , 30 ng/ml of PDGF-BB were added into the lower well to induce cell migration. After 6 hours of migration, the upper filter membrane surface was wiped to remove cells that had not migrated through the filter, and the filter was fixed and stained with 0.1% (w/v) Crystal Violet in 20% methanol for 15 minutes to identify cells on the lower filter membrane surface. The number of cells that migrated through the 0.8-mm 2 transwell membrane was counted in at least ten randomly-selected areas in triplicate for each condition and represented as the percentage of migration relative to control cells. For scratch wound healing assays, NIH-3T3, HeLa, Arl13b hnn or wild-type MEFs were grown to confluence and the monolayer scratched using 200 ml pipette plastic tips. After washing once with PBS, DMEM supplemented with 0.5% BSA was added together with PDGF-BB (30 ng/ml). Images were taken from each well immediately [time (t) 0] and after 8-16 hours. The area of cell migration from the initial wound edge was measured in ten random areas using Zeiss Axiovision software. Wound closure (%) was determined as follows: [12(wound area at t58-16 hours/wound area at t5 0 hours)6100]. For immunofluorescence analyses, slides were fixed in 4% paraformaldeyde for 15 minutes at room temperature and further processed for immunofluorescence, using Alexa-Fluor-568-conjugated phalloidin (0.2 units/ml, Invitrogen), anti-cortactin antibody (0.6 mg/ml, Millipore) and DAPI (1 mg/ml, Sigma), to stain nuclei.
Mass spectrometry
For mass spectrometry (MS), immunoprecipitated bands of interest were excised and digested with 6.7 ng/ml trypsin (Promega) in 50 mM NH 4 HCO 3 and incubated overnight at 37˚C. Digested peptides were desalted and concentrated with microcolumns produced in-house using GELoader tips packed with POROS R2 (Applied Biosystems, 20-mm bead size) and eluted directly onto the matrix-assisted laser desorption/ ionization (MALDI) plate using 0.6 ml of 5 mg/ml a-CHCA (a-cyano-4-hydroxy-trans-cinnamic acid, Sigma) in 50% (v/v) acetonitrile (ACN) with 5% (v/v) formic acid and allowed to air dry. MS and tandem MS (MS/MS) spectra were acquired using 4800 plus MALDI-time-of-flight (TOF)/TOF and using 4000 Series Explorer Software v.3.5.3 (Applied Biosystems). The mass spectrometer was externally calibrated using a standard peptide mixture containing angiotensin II (1046.2 Da), angiotensin I (1296.5 Da), neurotensin (1672.9 Da), ACTH (1-17; 2093.5 Da) and ACTH (18-39; 2465.7 Da) (LaserBio Labs). Each MS spectrum was acquired in a result-independent acquisition mode and the 10-15 strongest precursors were selected for MS/MS analyses. These were performed using collision-induced dissociation (CID) assisted with atmospheric air with acollision energy of 1 kV and a gas pressure of 1610 6 Torr. The MS and MS/MS data was analyzed in combined search mode (MS+MS/MS) using GPS Explorer Software v. 3.6 (Applied Biosystems) and the MASCOT search engine. The search parameters were as follows: monoisotopic peptide mass values were considered, maximum precursor mass tolerance (MS) of 50 ppm and a maximum fragment mass tolerance (MS/MS) of 0.3 Da. A maximum of two missed cleavages were allowed and no taxonomy restrictions were included. Carboxyamidomethylation of cysteines and oxidation of methionines were set as variable modifications. Protein identification was considered by use of significant homology scores if P,0.05 and if at least one peptide was fragmented.
Immunofluorescence
Cells grown on glass coverslips were serum-starved for 5 to 16 hours, stimulated or not with PDGF (30 ng/ml) for different times, washed with PBS and fixed in 4% paraformaldehyde in PBS for 15-20 minutes at room temperature. After quenching with 50 mM NH 4 Cl in PBS and blocking and permeabilizing with PBS, 0.5% BSA and 0.1% saponin for 10 minutes at room temperature, anti-Myh9, anti-cortactin, anti-EEA1 antibodies or Alexa-Fluor-568-conjugated phalloidin (0.2 to 0.8 U/ml) were added in the same buffer for 1 hour at room temperature and the cells were washed five times after each incubation. Secondary AlexaFluor-488-or -568-conjugated anti-rabbit or anti-mouse antibodies (Invitrogen) were used at 2-4 mg/ml. Coverslips were mounted in mounting medium [15% (w/v) vinol 205, 33% (v/v) glycerol, 0.1% azide in PBS] and analyzed in a Zeiss LSM 710 confocal microscope equipped with a Plan-Apochromat 636 1.40 NA oil Ph3 lens and Zeiss Zen 2010 software or a Leica TCS SP5 confocal microscope equipped with a HCX PL-APO 636 (NA 1.25-0.75) lens and Leica Application Suite software. Images were processed with ImageJ software, adjusting the levels or brightness of each channel up to a maximum threshold defined by the absence of signal in the negative controls.
Time-lapse fluorescence microscopy NIH-3T3 cells were grown in the eight-well Lab-Tek chambered #1.0 borosilicate coverglass system (Thermo Fisher) and transfected with Lifeact-ruby and Arl13b-wt-EGFP constructs using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After 24 hours, cells were serum-starved in DMEM without Phenol Red and supplemented with 0.5% BSA for 2 hours, and then imaged in the same medium before and after the addition of PDGF-BB (20 ng/ml). The images were acquired for 30 minutes at 60-second intervals by using an Andor Revolution XD system in a Nikon eclipse TiE spinning disk laser confocal microscope, equipped with a sensitive EMCCD camera and Plan Apo VC 606 1.4 NA objective at 37˚C and under 5% CO 2 .
Zebrafish in situ hybridization
Zebrafish embryos were obtained through natural crosses and staged according to Kimmel et al. (Kimmel et al., 1995) . The Arl13b morpholino was as described previously (Duldulao et al., 2009 ). Embryos were injected at the one-cell stage, fixed at 24 hours postfertilization and hybridized with a sox10 probe. Whole-mount in situ hybridization was performed as described previously (Thisse and Thisse, 2008) . Dioxigenin RNA probe was synthesized from a sox10 DNA template kindly provided by Robert N. Kelsh (University of Bath, UK; Dutton et al., 2001 ). All animal experiments were performed according to approved guidelines.
Statistical analysis
Numerical data are presented as mean6s.d. Statistical analysis was performed using GraphPad Prism (version 5.00, GraphPad Software). Two-way ANOVA or Student's t-tests were used for comparison between different data sets by using GraphPad Prism software.
